- Home
- ATRA vs OTLK Comparison
ATRA vs OTLK Comparison
Compare ATRA & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATRA | OTLK |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 37.5M |
| IPO Year | 2014 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ATRA | OTLK |
|---|---|---|
| Price | $9.82 | $1.59 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $5.00 | $2.50 |
| AVG Volume (30 Days) | 96.4K | ★ 31.0M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 122.52 | 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $120,772,000.00 | $8,146,123.00 |
| Revenue This Year | N/A | $1,430.98 |
| Revenue Next Year | N/A | $173.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.92 | $0.16 |
| 52 Week High | $19.15 | $3.39 |
Technical Indicators
Market Signals| Indicator | ATRA | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 54.32 | 84.97 |
| Support Level | $9.35 | $0.19 |
| Resistance Level | $11.35 | $2.09 |
| Average True Range (ATR) | 0.75 | 0.18 |
| MACD | -0.19 | 0.08 |
| Stochastic Oscillator | 27.30 | 85.85 |
Price Performance
Historical ComparisonAbout ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.